Novo Nordisk Shares Rise on Early Success of Ozempic Kidney Disease Trial

Novo Nordisk halting kidney trial early due to signs of success from interim analysis

Trial testing if diabetes drug Ozempic could delay kidney disease progression and lower death risk

Shares rose 2.5% in extended trading following the announcement

Ozempic contains semaglutide, also in Novo's weight loss drug Wegovy

Novo has seen high demand for semaglutide-based diabetes and weight loss drugs